tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Altimmune rallies after FDA accepts liver stiffness as MASH endpoint

The Food and Drug Administration’s Center for Drug Evaluation and Research, Office of New Drugs said it has accepted a letter of intent for the qualification of liver stiffness measurement by vibration-controlled transient elastography as a reasonably likely surrogate endpoint for clinical trials in adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis. Shares of Altimmune (ALT), which is developing a treatment for MAS, are up 7% to $3.68 following the FDA statement.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1